Introduction & Market Context
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) presented its first quarter 2026 financial results on May 6, 2026, revealing a complex picture of commercial momentum offset by near-term profitability challenges. While the company delivered 11% year-over-year revenue growth to $268.1 million, earnings per share of $0.02 fell significantly short of the $0.05 analyst forecast, representing a 60% miss. Despite this shortfall, investors responded positively in aftermarket trading, pushing shares up 1.25% to $22.63, suggesting confidence in the company’s reaffirmed full-year guidance and strategic trajectory.
The neurological and rare disease specialist maintained its fiscal 2026 revenue outlook of $1.22 billion to $1.28 billion, signaling management’s conviction that first-quarter headwinds represent temporary dynamics rather than structural challenges.
Quarterly Performance Highlights
As detailed in the company’s quarterly highlights, ACADIA demonstrated robust commercial execution across its two marketed franchises while managing a deliberate expansion of its commercial infrastructure.
DAYBUE (trofinetide) emerged as the quarter’s standout performer, generating $101.2 million in net sales—a 20% year-over-year increase that marked the highest growth rate since the third quarter of 2024. The company attributed this acceleration to record patient shipments and strong early adoption of DAYBUE STIX, a new formulation that received over 250 prescriptions in the first quarter alone, with approximately 30% coming from treatment-naïve or returning patients.
NUPLAZID (pimavanserin) contributed $166.9 million in net sales, representing 6% growth on a non-GAAP adjusted basis. The company noted that underlying demand remained strong at 8% year-over-year, with double-digit referral growth of 11% indicating sustained physician confidence in the Parkinson’s disease psychosis treatment.
The financial picture was complicated by a 35% surge in selling, general, and administrative expenses to $171.0 million, reflecting the company’s approximately 30% expansion of customer-facing teams. This strategic investment, while pressuring near-term profitability, positions ACADIA for accelerated growth in the second half of 2026. Research and development expenses declined modestly by 2% to $76.9 million as the company advanced multiple clinical programs toward key readouts.
Commercial Franchise Performance
The company’s presentation highlighted disciplined strategies to expand both DAYBUE and NUPLAZID market penetration through targeted investments in patient identification, awareness campaigns, and prescriber engagement.
For DAYBUE, the launch of DAYBUE STIX represents a meaningful product enhancement addressing caregiver concerns about ease of administration. One caregiver testimonial featured in the presentation emphasized the benefits: “You’ve taken the preservatives and the dye out…. and the ease is better. She takes it better. It’s easy to transport.” With caregiver satisfaction exceeding 80% and strong healthcare professional endorsement, STIX is expected to drive continued prescription growth while improving patient persistence.
The company also highlighted contributions from Named Patient Supply programs outside the United States, which provide access to trofinetide in markets where formal regulatory approval is pending. This global engagement strategy reflects ACADIA’s commitment to expanding patient access while building commercial infrastructure for potential future launches.
NUPLAZID’s performance reflected the resolution of a temporary “late to fill” dynamic that occurred within the quarter, masking underlying demand strength. The 11% year-over-year referral growth demonstrates robust top-of-funnel performance, which management expects to translate into sustained revenue growth as the expanded sales force matures.
The company’s renewed “More To Parkinson’s” campaign and enhanced direct-to-consumer initiatives aim to increase disease awareness and earlier patient activation. ACADIA maintained its goal of reaching approximately $1 billion in NUPLAZID sales by 2028, implying continued double-digit growth from current levels.
Pipeline and R&D Progress
ACADIA’s research and development presentation emphasized the breadth of its pipeline, with eight disclosed programs spanning neurological and rare diseases, along with multiple undisclosed initiatives.
The pipeline encompasses both marketed products (NUPLAZID and DAYBUE) and multiple investigational candidates across various development stages. Key programs include remlifanserin (ACP-204), a next-generation 5HT2A inverse agonist in Phase 2 for Alzheimer’s disease psychosis and Lewy body dementia with psychosis; ACP-211, a deuterated R-norketamine in Phase 2 for major depressive disorder; and ACP-711, a selective GABAA α3 modulator in Phase 1 for essential tremor.
In rare diseases, the company is advancing ACP-2591, a cGP analog in Phase 2 for Rett syndrome and Fragile X syndrome, and ACP-271, a GPR88 agonist in Phase 1 for Huntington’s disease and IND-enabling studies for tardive dyskinesia.
The company highlighted significant near-term catalysts, with Phase 2 remlifanserin results in Alzheimer’s disease psychosis expected between August and October 2026, and Phase 3 trofinetide data from Japan anticipated between September and November 2026. Management emphasized these readouts as critical value-creation drivers, with remlifanserin representing the largest near-term catalyst given the substantial unmet need in Alzheimer’s disease psychosis.
ACADIA projects five additional Phase 2 or Phase 3 study starts by the end of 2027, along with four Phase 2 or Phase 3 readouts during the same timeframe, underscoring the pipeline’s momentum and potential to drive long-term sustainable growth.
Financial Analysis and Guidance
Despite the first-quarter earnings miss, ACADIA’s financial position remains robust, with cash and investments totaling $851.5 million—an increase from $820 million at the end of the fourth quarter of 2025. This strong balance sheet provides strategic flexibility for business development activities, including potential acquisitions, licenses, and partnerships focused on neurological and rare diseases with high unmet medical needs.
The company reaffirmed its full fiscal year 2026 guidance across all key metrics. NUPLAZID net sales are projected between $760 million and $790 million, with gross-to-net adjustments of 22% to 24%. DAYBUE net sales, including contributions from named patient supply programs, are expected to reach $460 million to $490 million, also with 22% to 24% gross-to-net adjustments.
Research and development expenses are anticipated between $385 million and $410 million, while selling, general, and administrative expenses are projected at $660 million to $700 million. The SG&A guidance reflects the full-year impact of the commercial expansion initiated in late 2025 and early 2026.
Management’s confidence in reaffirming guidance despite the first-quarter miss suggests expectations for stronger performance in subsequent quarters as the expanded sales infrastructure matures and new product launches gain traction.
Strategic Outlook and Value Creation
ACADIA’s presentation concluded with a framework for value creation centered on three strategic pillars: remlifanserin development for Alzheimer’s disease psychosis, trofinetide expansion in Japan, and financial strength enabling business development.
The remlifanserin program represents ACADIA’s largest near-term value catalyst, building on the company’s extensive experience with pimavanserin and targeting a large, underserved Alzheimer’s disease psychosis population. Success in the Phase 2 program could validate a differentiated therapeutic approach and open a substantial commercial opportunity.
The trofinetide Japan Phase 3 study, if successful, would establish an important new market for DAYBUE and demonstrate the product’s potential for global expansion. This reflects ACADIA’s commitment to advancing patient access internationally while diversifying revenue sources.
With $851 million in cash and a clear focus on neurological and rare diseases with high unmet medical needs, ACADIA appears well-positioned to pursue strategic transactions that could accelerate growth and expand its commercial portfolio. The company’s presentation emphasized being “well positioned for both near-term catalysts and long-term sustainable growth,” a message that appears to have resonated with investors despite the first-quarter earnings shortfall.
The combination of commercial momentum in existing franchises, multiple pipeline catalysts in the coming months, and strong financial flexibility positions ACADIA to navigate near-term profitability pressures while building toward sustained value creation. However, execution on both commercial expansion and clinical development will be critical to validating management’s optimistic outlook and achieving the company’s ambitious growth targets.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Source:
www.investing.com
